These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29222833)

  • 1. Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the TROG 03.04 RADAR trial.
    Marcello M; Ebert MA; Haworth A; Steigler A; Kennedy A; Bulsara M; Kearvell R; Joseph DJ; Denham JW
    J Med Imaging Radiat Oncol; 2018 Apr; 62(2):248-255. PubMed ID: 29222833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality improvements in prostate radiotherapy: outcomes and impact of comprehensive quality assurance during the TROG 03.04 'RADAR' trial.
    Kearvell R; Haworth A; Ebert MA; Murray J; Hooton B; Richardson S; Joseph DJ; Lamb D; Spry NA; Duchesne G; Denham JW
    J Med Imaging Radiat Oncol; 2013 Apr; 57(2):247-57. PubMed ID: 23551788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates?
    Ebert MA; Bulsara M; Haworth A; Kearvell R; Richardson S; Kennedy A; Spry NA; Bydder SA; Joseph DJ; Denham JW
    J Med Imaging Radiat Oncol; 2015 Feb; 59(1):99-108. PubMed ID: 25082363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial.
    Joseph D; Denham JW; Steigler A; Lamb DS; Spry NA; Stanley J; Shannon T; Duchesne G; Atkinson C; Matthews JHL; Turner S; Kenny L; Christie D; Tai KH; Gogna NK; Kearvell R; Murray J; Ebert MA; Haworth A; Delahunt B; Oldmeadow C; Attia J
    Int J Radiat Oncol Biol Phys; 2020 Mar; 106(4):693-702. PubMed ID: 32092343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.
    Denham JW; Steigler A; Joseph D; Lamb DS; Spry NA; Duchesne G; Atkinson C; Matthews J; Turner S; Kenny L; Tai KH; Gogna NK; Gill S; Tan H; Kearvell R; Murray J; Ebert M; Haworth A; Kennedy A; Delahunt B; Oldmeadow C; Holliday EG; Attia J
    Radiother Oncol; 2015 Jun; 115(3):301-7. PubMed ID: 26072289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
    Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
    BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benchmarking dosimetric quality assessment of prostate intensity-modulated radiotherapy.
    Senthi S; Gill SS; Haworth A; Kron T; Cramb J; Rolfo A; Thomas J; Duchesne GM; Hamilton CH; Joon DL; Bowden P; Foroudi F
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):998-1005. PubMed ID: 21310548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.
    Sridharan S; Steigler A; Spry NA; Joseph D; Lamb DS; Matthews JH; Atkinson C; Tai KH; Duchesne G; Christie D; Attia J; Holliday EG; Denham JW
    Radiother Oncol; 2016 Oct; 121(1):98-102. PubMed ID: 27528117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between treatment planning and delivery factors and disease progression in prostate cancer radiotherapy: Results from the TROG 03.04 RADAR trial.
    Marcello M; Ebert M; Haworth A; Steigler A; Kennedy A; Joseph D; Denham J
    Radiother Oncol; 2018 Feb; 126(2):249-256. PubMed ID: 29122360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric intercomparison for two Australasian clinical trials using an anthropomorphic phantom.
    Kron T; Hamilton C; Roff M; Denham J
    Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):566-79. PubMed ID: 11872306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
    Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
    Denham JW; Nowitz M; Joseph D; Duchesne G; Spry NA; Lamb DS; Matthews J; Turner S; Atkinson C; Tai KH; Gogna NK; Kenny L; Diamond T; Smart R; Rowan D; Moscato P; Vimieiro R; Woodfield R; Lynch K; Delahunt B; Murray J; D'Este C; McElduff P; Steigler A; Kautto A; Ball J
    BJU Int; 2014 Sep; 114(3):344-53. PubMed ID: 24512527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).
    Steigler A; Mameghan H; Lamb D; Joseph D; Matthews J; Franklin I; Turner S; Spry N; Poulsen M; North J; Kovacev O; Denham J
    Australas Radiol; 2000 Feb; 44(1):65-71. PubMed ID: 10761262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
    Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
    Kassim I; Dirkx ML; Heijmen BJ
    Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.